287 related articles for article (PubMed ID: 28675058)
1. Selumetinib for the treatment of non-small cell lung cancer.
Casaluce F; Sgambato A; Maione P; Sacco PC; Santabarbara G; Gridelli C
Expert Opin Investig Drugs; 2017 Aug; 26(8):973-984. PubMed ID: 28675058
[TBL] [Abstract][Full Text] [Related]
2. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
Jänne PA; Shaw AT; Pereira JR; Jeannin G; Vansteenkiste J; Barrios C; Franke FA; Grinsted L; Zazulina V; Smith P; Smith I; Crinò L
Lancet Oncol; 2013 Jan; 14(1):38-47. PubMed ID: 23200175
[TBL] [Abstract][Full Text] [Related]
3. Selumetinib in advanced non small cell lung cancer (NSCLC) harbouring KRAS mutation: endless clinical challenge to KRAS-mutant NSCLC.
Paolo M; Assunta S; Antonio R; Claudia SP; Anna BM; Clorinda S; Francesca C; Fortunato C; Cesare G
Rev Recent Clin Trials; 2013 Jun; 8(2):93-100. PubMed ID: 24063423
[TBL] [Abstract][Full Text] [Related]
4. Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (SELECT-1).
Jänne PA; Mann H; Ghiorghiu D
Clin Lung Cancer; 2016 Mar; 17(2):e1-4. PubMed ID: 26837474
[TBL] [Abstract][Full Text] [Related]
5. Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer.
Metro G; Chiari R; Baldi A; De Angelis V; Minotti V; Crinò L
Future Oncol; 2013 Feb; 9(2):167-77. PubMed ID: 23414467
[TBL] [Abstract][Full Text] [Related]
6. SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer.
Soria JC; Fülöp A; Maciel C; Fischer JR; Girotto G; Lago S; Smit E; Ostoros G; Eberhardt WEE; Lishkovska P; Lovick S; Mariani G; McKeown A; Kilgour E; Smith P; Bowen K; Kohlmann A; Carlile DJ; Jänne PA
Ann Oncol; 2017 Dec; 28(12):3028-3036. PubMed ID: 29045535
[TBL] [Abstract][Full Text] [Related]
7. Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.
Jänne PA; Smith I; McWalter G; Mann H; Dougherty B; Walker J; Orr MC; Hodgson DR; Shaw AT; Pereira JR; Jeannin G; Vansteenkiste J; Barrios CH; Franke FA; Crinò L; Smith P
Br J Cancer; 2015 Jul; 113(2):199-203. PubMed ID: 26125448
[TBL] [Abstract][Full Text] [Related]
8. Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
Jänne PA; van den Heuvel MM; Barlesi F; Cobo M; Mazieres J; Crinò L; Orlov S; Blackhall F; Wolf J; Garrido P; Poltoratskiy A; Mariani G; Ghiorghiu D; Kilgour E; Smith P; Kohlmann A; Carlile DJ; Lawrence D; Bowen K; Vansteenkiste J
JAMA; 2017 May; 317(18):1844-1853. PubMed ID: 28492898
[TBL] [Abstract][Full Text] [Related]
9. Selumetinib in the treatment of non-small-cell lung cancer.
Bernabé R; Patrao A; Carter L; Blackhall F; Dean E
Future Oncol; 2016 Nov; 12(22):2545-2560. PubMed ID: 27467210
[TBL] [Abstract][Full Text] [Related]
10. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
[TBL] [Abstract][Full Text] [Related]
11. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
Carter CA; Rajan A; Keen C; Szabo E; Khozin S; Thomas A; Brzezniak C; Guha U; Doyle LA; Steinberg SM; Xi L; Raffeld M; Tomita Y; Lee MJ; Lee S; Trepel JB; Reckamp KL; Koehler S; Gitlitz B; Salgia R; Gandara D; Vokes E; Giaccone G
Ann Oncol; 2016 Apr; 27(4):693-9. PubMed ID: 26802155
[TBL] [Abstract][Full Text] [Related]
12. Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer.
Zhou J; Zhang S; Chen X; Zheng X; Yao Y; Lu G; Zhou J
Cancer Lett; 2017 Nov; 408():130-137. PubMed ID: 28866094
[TBL] [Abstract][Full Text] [Related]
13. Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.
van Brummelen EMJ; Huijberts S; van Herpen C; Desar I; Opdam F; van Geel R; Marchetti S; Steeghs N; Monkhorst K; Thijssen B; Rosing H; Huitema A; Beijnen J; Bernards R; Schellens J
Oncologist; 2021 Apr; 26(4):290-e545. PubMed ID: 33296125
[TBL] [Abstract][Full Text] [Related]
14. Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219.
Melosky B; Bradbury P; Tu D; Florescu M; Reiman A; Nicholas G; Basappa N; Rothenstein J; Goffin JR; Laurie SA; Wheatley-Price P; Leighl N; Goss G; Reaume MN; Butts C; Murray N; Card C; Ko J; Blais N; Gray S; Lui H; Brown-Walker P; Kaurah P; Prentice LM; Seymour L
Lung Cancer; 2019 Jul; 133():48-55. PubMed ID: 31200828
[TBL] [Abstract][Full Text] [Related]
15. The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma.
Biernacka A; Tsongalis PD; Peterson JD; de Abreu FB; Black CC; Gutmann EJ; Liu X; Tafe LJ; Amos CI; Tsongalis GJ
Cancer Genet; 2016 May; 209(5):195-8. PubMed ID: 27068338
[TBL] [Abstract][Full Text] [Related]
16. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
Douillard JY; Shepherd FA; Hirsh V; Mok T; Socinski MA; Gervais R; Liao ML; Bischoff H; Reck M; Sellers MV; Watkins CL; Speake G; Armour AA; Kim ES
J Clin Oncol; 2010 Feb; 28(5):744-52. PubMed ID: 20038723
[TBL] [Abstract][Full Text] [Related]
17. Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations.
Abdel-Rahman O
Ther Adv Respir Dis; 2016 Jun; 10(3):265-74. PubMed ID: 26893312
[TBL] [Abstract][Full Text] [Related]
18. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
19. Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation.
Imyanitov EN; Levchenko EV; Kuligina ES; Orlov SV
Expert Opin Pharmacother; 2020 Nov; 21(16):1943-1953. PubMed ID: 32880495
[TBL] [Abstract][Full Text] [Related]
20. MEK inhibitors under development for treatment of non-small-cell lung cancer.
Kim C; Giaccone G
Expert Opin Investig Drugs; 2018 Jan; 27(1):17-30. PubMed ID: 29216787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
